A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma

Journal of Immunology

Volumn 160, Issue 12, 1998, Pages 5869-5873

  Kobayashi, Makiko ^a   Kobayashi, Hiroyuki ^a   Pollard, Richard B ^a   Suzuki, Fujio ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; LUNG METASTASIS; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; INTERLEUKIN-10; INTERLEUKIN-4; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PROTEIN KINASES; TH2 CELLS;

EID: 0032526906     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Werkmeister, J., W. McCarthy, and P. Mersey. 1981. Suppressor cell activity in melanoma patients. I. Relation to tumor growth and immunoglobulin levels in vitro. Int. J. Cancer 28:1.
2. Mukherji, B., S. A. Wilhelm, A. Guha, and M. T. Ergin. 1986. Regulation of cellular responses against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J. Immunol. 136:1888.
3. North, R. J., M. Awwad, and P. L. Dunn. 1989. The immune response to tumors. Transplant. Proc. 21:575.
4. Vaage, J. 1974. Circulating tumor antigens versus immune serum factors in depressed concomitant immunity. Cancer Res. 34:2979.
5. Sjögren, H. O., I. Hellström, S. C. Bansal, and K. E. Hellström. 1971. Suppressive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen-antibody complexes. Proc. Natl. Acad. Sci. USA 68:1372.
6. Romeo, D. S., and S. B. Mizel. 1988. Partial purification of an immunosuppressive protein from human tumor cell line and analysis of its relationship to transforming growth factor. Cell. Immunol. 122:483.
7. Fu, Y. X., G. A. Watson, M. Kasahara, and D. M. Lopez. 1991. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. J. Immunol. 146:783.
8. 2-dependent and -independent immune suppressor cells by tumor-derived GM-CSF and M-CSF. J. Leukocyte Biol. 53:86.
9. Gorelik, L., A. Prokhorova, and M. B. Mokyr. 1994. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing MOPC-315 tumor. Cancer Immunol. Immunother. 39:117.
10. Putnam, J. B., and J. A. Roth. 1985. Identification and characterization of a tumor-derived immunosuppressive glycoprotein from murine melanoma K-1735. Cancer Immunol. Immunother. 19:90.
11. Sami, S., S. Takano, T. Majima, H. Aso, T. Nakamura, and N. Ishida. 1986. Low molecular weight immunosuppressive factors found in elevated amounts in cancer ascitic fluids of mice. J. Immunopharmacol. 8:39.
12. Yamamura, M., R. L. Modlin, J. D. Ohmen, and R. L. Moy. 1993. Local expression of antiinflammatory cytokines in cancer. J. Clin. Invest. 91:1005.
13. + T helper subsets in human melanoma. Surgery 117:317.
14. Nishioka, Y., S. Sone, E. Orino, A. Nii, and T. Ogura. 1991. Down-regulation by interleukin-4 of activation of human alveolar macrophages to the tumoricidal state. Cancer Res. 51:5526.
15. Lindquist, C., A. L. Ostman, C. Okerblom, and K. Akerman. 1992. Decreased interleukin-2 β chain receptor expression by interleukin-4 on LGL: influence on the IL-2 induced cytotoxicity and proliferation. Cancer Lett. 64:43.
16. Moore, K. W., A. O'Garra, R. de Waal Malefyt, P. Vieira, and T. R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immunol. 11:165.
17. Poste, G., and G. L. Nicolson. 1980. Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc. Natl. Acad. Sci. USA 77:399.
18. Hill, R. P., and V. Ling. 1984. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. Science 224:998.
19. Poste, G., and I. J. Fidler. 1980. The pathogenesis of cancer metastasis. Nature 283:139.
20. Nabi, I. R., and A. Raz. 1988. Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant. Cancer Res. 48:1258.
21. Dumont, J. A., W. D. Jones, Jr., and A. J. Bitonri. 1992. Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C. Cancer Res. 52:1195.
22. Herd, Z. L. 1987. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies. Cancer Res. 47:2696.
23. + T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type tubercle bacilli. J. Natl. Cancer Inst. 77:441.
24. + contrasuppressor T cells improve the resistance of thermally injured mice infected with HSV. J. Leukocyte Biol. 57:159.
25. Yokoyama, T., O. Yoshie, H. Aso, T. Ebina, and N. Ishida. 1986. Inhibition of intravascular mouse melanoma dissemination by recombinant human interferon α A/D. Jpn. J. Cancer Res. 77:80.
26. Matsuo, R., M. Kobayashi, D. N. Herndon, R. B. Pollard, and F. Suzuki. 1996. Interleukin-12 protects thermally injured mice from herpes simplex virus type 1 infection. J. Leukocyte Biol. 59:623.
27. Ghosh, P., K. L. Komschlies, M. Cippitelli, D. L. Longo, J. Subleski, J. Ye, A. Sica, H. A. Young, R. H. Wiltrout, and A. C. Ochoa. 1995. Gradual loss of T-helper 1 populations in spleens of mice during progressive tumor growth. J. Natl. Cancer Inst. 87:1478.
28. Maeda, H., and A. Shiraishi. 1996. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 156:73.
29. McAdam, A. J., B. A. Pulaski, S. S. Harkins, E. K. Hutter, E. M. Lord, and J. G. Frelinger. 1995. Synergistic effects of co-expression of the Th1-cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells. Int. J. Cancer 61:628.
30. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother. 42:1.
31. Handel-Fernandez, M. E., X. Cheng, L. M. Herbert, and D. M. Lopez. 1997. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J. Immunol. 158:280.
32. Maeda, H., H. Kuwahara, Y. Ichimura, M. Ohtsuki, S. Kurakata, and A. Shiraishi. 1995. TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol. 155:4926.
33. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547.
34. + T cells to enhance priming for interferon-γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90:1018.
35. Manetti, R., P. Parronchi, M. G. Giudizi, M. P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin-12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199.
36. + T cells. J. Immunol. 154:5071.
37. Nastala, C. L., H. D. Edington, and T. G. McKinney. 1994. Recombinant interleukin-12 (IL-12) administration induces tumor regression in association with interferon-γ production. J. Immunol. 153:1697.
38. Takeuchi, T., T. Ueki, Y. Sasaki, T. Kajiwara, B. Li, N. Moriyama, and K. Kawabe. 1997. Th2-line response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol. Immunother. 43:375.
39. Obiri, N. I., G. G. Hillman, G. P. Haas, S. Sud, and R. K. Puri. 1993. Expression of high affinity interleukin-4 receptors on human renal carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J. Clin. Invest. 91:88.
40. Topp, M. S., M. Koenigsmann, A. Mire-Sluis, D. Oberberg, F. Eitelbach, Z. Von Marschall, M. Notter, B. Reufi, H. Stein, E. Thiel, and W. E. Berder. 1993. Interleukin 4 inhibits growth of a human lung tumor cell line in vitro and has therapeutic activity against xenografts of this cell line in vitro. Int. J. Oncol. 3:167.
41. Margolin, K., F. R. Aronson, M. Sznol, M. B. Atkins, R. Gucalp, R. I. Fisher, M. Sunderland, J. H. Doroshow, M. L. Ernest, J. W. Mier, J. P. Dutcher, E. R. Gaynor, and G. R. Weiss. 1994. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J. Immunother. 15:147.
42. Schmidt-Wolf, G., and I. G. H. Schmidt-Wolf. 1995. Cytokines and clinical gene therapy. Eur. J. Immunol. 25:1137.
43. Tepper, R. I., P. K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
44. Tepper, R. I., R. L. Coffman, and P. Leder. 1992. An eosinophil-dependent mechanism for the antitumor effect of IL-4. Science 257:548.
45. Gallagher, G., and Y. Zaloom. 1992. Peritumoral IL-4 treatment induces systemic inhibition of tumor growth in experimental melanoma. Anticancer Res. 12:1019.
46. Yu, S. J., M. X. Wei, E. A. Chiocca, R. L. Martuza, and R. L. Tepper. 1993. Treatment of glioma by engineered interleukin-4-secreting cells. Cancer Res. 53:3125.
47. Krauss, J. C., S. E. Strome, A. E. Chang, and S. Shu. 1994. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J. Immunother. Emphas. Tumor Immunol. 16:77.
48. Souberbielle, B. E., B. C. Knight, M. J. Morrow, D. Darling, M. Fraziano, J. B. Marriott, S. Cookson, F. Farzaneh, and A. G. Dalgleish. 1996. Comparison of IL-2 and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumor vaccine. Gene Ther. 3:853.
49. Lipshy, K. A., P. J. Kostuchenko, G. G. Hamad, C. E. Bland, S. K. Barrett, and H. D. Bear. 1997. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma. Ann. Surg. Oncol. 4:334.
50. Riemann, D., A. Kehlen, and J. Langner. 1995. Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13. Clin. Exp. Immunol. 100:277.
51. Wei, M. X., T. Tamiya, R. K. Hurford, Jr., E. J. Boviatsis, R. I. Tepper, and A. Chiocca. 1995. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum. Gene Ther. 6:437.
52. Missol, E., A. Sochanik, and S. Szala. 1995. Introduction of murine IL-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. Cancer Lett. 7:189.
53. Hurford, R. K., Jr., G. Dranoff, R. C. Mulligan, and R. I. Tepper. 1995. Gene therapy of metastatic cancer by in vitro retroviral gene targeting. Nat. Genet. 10:430.
54. Schleimer, R. P., S. A. Sterbinsky, J. Kaiser, C. A. Bickel, D. A. Klunk, K. Tomioka, W. Newman, F. W. Luscinskas, M. A. Gimbrone, and B. M. McIntyre. 1992. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium association with expression of VCAM-1. J. Immunol. 148:1086.